Abstract
Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.
Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists
Current Signal Transduction Therapy
Title: Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Volume: 3 Issue: 3
Author(s): Simone Fulda
Affiliation:
Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists
Abstract: Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.
Export Options
About this article
Cite this article as:
Fulda Simone, Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs), Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699686
DOI https://dx.doi.org/10.2174/157436208785699686 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology Neural Stem Cells - A Promising Potential Therapy for Brain Tumors
Current Stem Cell Research & Therapy Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma
Current Cancer Drug Targets The Synthesis and Use of Boronated Amino Acids for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry STAT3 Regulation of Glioblastoma Pathogenesis
Current Molecular Medicine Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis and Therapy
Current Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides
Current Medicinal Chemistry TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine